Saffron for Depression (2026): The Botanical with SSRI-Comparable RCT Data — Akhondzadeh 2005, Lopresti 2014 Systematic Review, the 30 mg Studied Dose, and Why 9 of 9 Products in Our Catalog Still Cap at Standard

September 6, 2026

TL;DR — the bottom line

Saffron at 30 mg/day of standardized extract has RCT evidence comparable to fluoxetine 20 mg for mild-to-moderate depression. This is one of the few botanicals with real head-to-head SSRI trial data.

Saffron (Crocus sativus stigma extract) is not another wellness-marketed "mood support" ingredient with weak evidence. It has been directly randomized against a first-line SSRI in multiple trials and has demonstrated statistically comparable efficacy on the Hamilton Depression Rating Scale at 6 weeks (Akhondzadeh et al. 2005). Lopresti & Drummond 2014 systematic-reviewed five saffron RCTs and confirmed the effect versus placebo. Kashani et al. 2017 replicated in postpartum depression. This is a real evidence base.

9 saffron products in the Vyvata catalog. Top cluster at 62-65 Standard. Zero Verified. Zero Elite.
Studied dose: 30 mg/day of standardized saffron extract — matched in most products by an 88.5 mg tablet/capsule using the affron® (Pharmactive) or a similar standardized formulation.
Effect appears at 2-6 weeks in the RCT literature — comparable to SSRI onset.
The tier ceiling (no Verified) is not because saffron doesn't work — it's because the category's products cap on transparency (crocin + safranal % standardization), third-party testing, and post-market safety documentation.
Safety flag: saffron is a serotonergic-active compound. It should NOT be combined with SSRIs, SNRIs, MAOIs, or triptans without physician oversight — serotonin syndrome risk.

⚠ Read this before anything else

Saffron is a serotonergic compound. If you are currently taking a prescription antidepressant (SSRI, SNRI, MAOI, TCA, or a triptan for migraine), do not add saffron without your prescribing clinician's oversight. The saffron-antidepressant interaction is not extensively characterized in humans but the theoretical risk of serotonin syndrome is real. If you are self-managing mild-to-moderate depression and have never been prescribed an antidepressant, saffron is a reasonable evidence-anchored option to discuss with a licensed clinician. If you are already on medication, the answer is not to add saffron — the answer is to have a conversation with your prescriber about your treatment plan.

This article is educational content about supplement scoring and evidence. It is not medical advice. Depression is a serious clinical condition that warrants professional care.

Section 1 — The Akhondzadeh 2005 headline: saffron 30 mg vs fluoxetine 20 mg

Akhondzadeh et al. 2005 (Phytotherapy Research)

Design: 6-week, double-blind, randomized trial in 40 adult outpatients with mild-to-moderate major depression (DSM-IV). Intervention arm: saffron petal extract 15 mg twice daily (30 mg/day total). Control arm: fluoxetine 10 mg twice daily (20 mg/day total — the standard starting dose for depression).

Primary outcome: Hamilton Depression Rating Scale (HAM-D) change from baseline. Result: both groups showed significant improvement from baseline; between-group differences were not statistically significant. Both interventions produced clinically meaningful reductions in HAM-D scores over 6 weeks. Withdrawal rates and adverse events were comparable.

Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Phytotherapy Research 2007;21(4):383-387. · Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology 2005;97(2):281-284.

A single small pilot trial is not proof. But the Akhondzadeh finding was replicated multiple times in the following decade, in different depression subtypes and with different comparator drugs. The result is one of the most consistent botanical-vs-SSRI head-to-head signals in the depression literature.

Section 2 — The broader RCT evidence base

Lopresti & Drummond 2014 systematic review

Lopresti & Drummond 2014 (Human Psychopharmacology) systematically reviewed 6 RCTs of saffron for depression. Trials compared saffron against placebo, fluoxetine, or imipramine. Effect sizes on standardized depression rating scales favored saffron over placebo consistently, and were non-inferior to the SSRI/TCA comparators in the head-to-head trials. Dose across trials clustered at 30 mg/day of standardized extract.

Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human Psychopharmacology 2014;29(6):517-527.

Kashani et al. 2017 — postpartum depression

Kashani et al. 2017 (Pharmacopsychiatry) — 6-week RCT in 60 women with mild-to-moderate postpartum depression. Saffron 15 mg twice daily vs placebo. Significant reduction in Edinburgh Postnatal Depression Scale scores at 6 weeks. Effect size clinically meaningful. This is one of the few RCT-tested "natural" interventions in the specific postpartum-depression context.

Kashani L, Eslatmanesh S, Saedi N, et al. Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. Pharmacopsychiatry 2017;50(2):64-68.

Ghajar et al. 2017 — as an SSRI adjunct

Ghajar et al. 2017 (Psychopharmacology) — 6-week RCT in 40 patients with major depression on stable citalopram treatment, randomized to add saffron 30 mg/day vs placebo. Adjunct saffron produced additional HAM-D improvement over citalopram alone.

Important: this trial was done under close psychiatric supervision. It is NOT a green light for self-administered SSRI + saffron combinations at home. The serotonin-syndrome caution above still applies.

Ghajar A, Neishabouri SM, Velayati N, et al. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. Pharmacopsychiatry 2017;50(4):152-160.

Mechanistic evidence — how saffron may work

The proposed mechanisms include serotonin reuptake inhibition (crocin appears to have SSRI-like activity at brain synapses in animal work), MAO inhibition at higher doses, NMDA receptor modulation (safranal), and increased brain-derived neurotrophic factor (BDNF) — the same downstream pathway SSRIs eventually engage over 4-6 weeks. The three most-studied bioactive compounds are crocin (a carotenoid-derived glycoside responsible for saffron's color), safranal (a volatile aldehyde responsible for the aroma), and picrocrocin (a bitter compound). Standardized extracts specify crocin + safranal content by percentage.

Hosseinzadeh H, Nassiri-Asl M. Avicenna's (Ibn Sina) the Canon of Medicine and Saffron (Crocus sativus L.): a review. Phytotherapy Research 2013;27(4):475-483.

Section 3 — Dose + standardization: what actually to look for

The studied saffron dose vs common label formats

Product format	Label serving	Approx saffron extract delivered	Servings to reach 30 mg studied dose
Standardized extract capsule — 88.5 mg (Ascent Nutrition, NusaPure)	88.5 mg extract	~30 mg of standardized saffron equivalent (the reference dose)	1 capsule/day = studied dose
Standardized affron® extract — 14 mg or 28 mg (Pharmactive branded)	14-28 mg	affron® is a specific 3.5% total lepticrosalides standardized extract; 14 mg branded = ~30 mg equivalent	1-2 capsules/day depending on brand's dose per cap
Whole ground stigma powder (unstandardized)	100-500 mg	Crocin + safranal % variable batch-to-batch; may or may not match extract dose	Difficult to know — dose adequacy is a guessing game
Saffron tincture (unspecified standardization)	1 mL (typical dropper)	Widely variable — some tinctures are dilute enough that reaching 30 mg equivalent is impractical	Product-dependent; often not documented

The shorthand: if a saffron product's label does not disclose crocin/safranal % standardization AND the equivalent dose in mg of standardized saffron, you cannot know whether the product matches the RCT dose. The category standard is 30 mg/day of a 3-3.5% total lepticrosalides-standardized extract, often expressed as 88.5 mg of a specific extract formulation.

Section 4 — Why 9 of 9 products cap at Standard (62-65/100)

The saffron evidence is strong. The category's product tier ceiling is not. Here is what the top-scoring products got right and where the transparency + testing gap keeps them out of Verified.

The 9 saffron products in the Vyvata catalog

Score	Tier	Product	Why it scored here
65	Standard	Ascent Nutrition Saffron Extract — 88.5 mg × 60 caps	Matches the 88.5 mg / ~30 mg equivalent studied-dose format. Vendor identification present. Standard-tier ceiling on third-party crocin/safranal % testing documentation.
64	Standard	Saffron Extract (generic)	Standardized-extract format, but vendor identification less clear. Matches evidence-anchored dose.
63	Standard	Full Spectrum Saffron Whole Ground Stigmas	Whole-stigma format — closer to the traditional preparation but harder to standardize. Would need per-batch crocin/safranal analytical data to score higher.
62	Standard	NusaPure Saffron Extract 88.5 mg × 200 caps	Reference-dose format at value pricing. Standard-tier ceiling due to third-party testing + long-term safety documentation gaps.
58	Standard	JOYFUL SAFFRON ASHWAGANDHA (UpNourish)	Combination product with ashwagandha — the individual doses of each ingredient are harder to standardize against the reference RCT protocols.
55	Standard	Saffron Capsules Vitamin Dietary Supplement	Generic labeling. Dose adequacy unclear from label alone.
48	Rejected	Pure Saffron – Balance in Harmony	Marketing framing raises unverified-mood-support-claim red flags per the rubric.
44	Rejected	Saffron Extract (Rejected)	Dose or standardization documentation gaps triggered rubric flags.
44	Rejected	Mood Boost, Saffron Tincture (Evergreen Apothecary)	Tincture format — dose adequacy vs the 30 mg standardized-extract RCT dose is not documented on label. Mood-boost naming triggers the transparency rubric line.

What the top-cluster products would need to graduate to Verified

Three things separate the Standard-tier ceiling from Verified in this category:

Certificate of Analysis with crocin + safranal % analytical data per batch — most consumer saffron products do not publish this. Standardized extracts (affron®, others) provide this at the ingredient supplier level but the retail brand does not always pass the data through to the customer.
Third-party heavy-metal + adulterant testing — saffron is one of the most-adulterated agricultural products in the world (dyed marigold petals, safflower, turmeric adulteration all documented). Independent adulterant testing per batch is a meaningful quality signal.
Long-term safety documentation — most saffron RCTs are 6-8 weeks. Long-term daily use (6-24 months) is less well-characterized. Products would score higher with published post-market surveillance or extension study data.

The rubric does not penalize saffron for the RCT evidence. It rewards products that go the extra mile on transparency, testing, and long-term safety documentation. That distinction is what separates a 62/100 Standard from a 70/100 Verified in this category.

Section 5 — Practical shopping: 4 questions to answer before buying

The 4 questions

Is it a standardized extract or unstandardized whole stigma? Standardized extract (specifically 3-3.5% total lepticrosalides, or an affron®-style branded standardization) is what the RCTs used. Whole stigma is traditional but harder to dose-match to the evidence.
Does one serving deliver the equivalent of 30 mg standardized extract? An 88.5 mg extract capsule typically delivers this. An affron® branded product will specify. A generic capsule or tincture may not.
Is there a third-party Certificate of Analysis available? Saffron is a heavily-adulterated crop — insist on adulterant testing where possible.
Are you currently taking any serotonergic medication? SSRI, SNRI, MAOI, TCA, or triptan — do NOT self-combine with saffron without your prescriber's oversight. This is the safety line the marketing side of this category does not always highlight.

Section 6 — What we don't know

Does saffron work for major depression (not just mild-to-moderate)?

Insufficient RCT data. The existing evidence base is almost entirely in mild-to-moderate depression. Severe or treatment-resistant depression has not been meaningfully tested with saffron monotherapy. The answer is not "saffron probably works there too" — the answer is "we don't know, and severe depression warrants professional psychiatric care."

How long is safe daily saffron use at 30 mg/day?

RCT durations are typically 6-8 weeks. Longer-term daily use (6-24 months) is less well-characterized. Higher doses (100+ mg/day) have been associated with adverse effects in some case reports. The 30 mg/day dose has a good short-term safety profile in the published literature.

Are the effects sustained after stopping?

Not well-studied. Most trials measured effect only during the intervention period. Whether depression symptoms rebound after discontinuation is not clearly documented in the current RCT literature.

Which specific standardized extract (affron® vs generic) is best?

affron® has the largest RCT dataset because it is a research-supported branded ingredient. Generic standardized extracts at matched crocin/safranal % are chemically similar but do not carry the same brand-specific RCT provenance. Both can deliver the studied dose.

Frequently asked questions

Is saffron better than an SSRI for depression?

Not clearly. The head-to-head RCTs (Akhondzadeh 2005, Kashani 2017) showed saffron is comparable to fluoxetine at 6 weeks in mild-to-moderate depression, not superior. "Better" is a subjective evaluation that depends on side effect profile, tolerability, cost, and the specific patient. Saffron has a milder short-term side effect profile in the published trials; SSRIs have decades of larger-scale safety data. The evidence does not support a blanket "saffron > SSRI" claim in either direction.

Can I take saffron with my SSRI?

Only with your prescriber's oversight. The Ghajar 2017 trial did combine saffron + citalopram under close psychiatric supervision and reported additional benefit — but that trial is not a green light for at-home self-combination. Serotonin syndrome, though rare, is a real risk when serotonergic agents are combined. Talk to your prescribing clinician.

How fast does saffron work?

The RCT data suggests measurable improvement on standardized depression rating scales at 2-6 weeks — comparable to SSRI onset. This is not a same-day mood boost like caffeine. Saffron works, if it works for you, on the timescale antidepressants generally work.

Does saffron help with anxiety?

Preliminary evidence suggests yes for mild-to-moderate anxiety (Mazidi 2016, Kell 2017 small trials). The evidence base is smaller than for depression and dosing is still being characterized.

What if I don't feel any effect?

Depression treatment response is highly individual. If a 6-8 week trial of standardized saffron at 30 mg/day produces no meaningful benefit, that is diagnostically useful information — it warrants a conversation with a licensed clinician rather than dose escalation on your own. Higher saffron doses (100+ mg) have been associated with adverse effects.

Does culinary saffron in food count?

No, meaningfully. Culinary saffron is used in tiny amounts — a pinch flavors a paella. To reach the 30 mg/day extract-equivalent, you would need to consume culinary saffron at doses that would be economically absurd and gastronomically unpleasant. The evidence base is for standardized capsule extracts, not for saffron as a spice.

Where can I read your scoring methodology?

Our 6-dimension rubric is applied uniformly to every supplement product in the catalog. The scoring-integrity policy documents the rules that prevent score manipulation. Every scoring commit lands in the public GitHub repository with evidence artifacts.

Item added to your cart